Trasylol Purple Book BLA 020304

BLA number
020304
Proprietary names
Trasylol
Proper names
aprotinin
Applicant
Bayer HealthCare Pharmaceuticals Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Trasylolaprotinin351(a)1,000,000KIU/100ML (10,000KIU/ML)InjectionIntravenousSingle-Dose VialDiscLicensed1993-12-29
002Trasylolaprotinin351(a)2,000,000KIU/200ML (10,000KIU/ML)InjectionIntravenousSingle-Dose VialDiscLicensed1993-12-29

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-08-01U001Trasylol351(a)DiscBayer HealthCare Pharmaceuticals Inc.
2020-08-01U002Trasylol351(a)DiscBayer HealthCare Pharmaceuticals Inc.
2020-05-01R001Trasylol351(a)DiscBayer HealthCare Pharmaceuticals Inc.
2020-05-01R002Trasylol351(a)DiscBayer HealthCare Pharmaceuticals Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Trasylol351(a)DiscLicensed1993-12-29
2020-05-01002Trasylol351(a)DiscLicensed1993-12-29